{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:12:35Z","timestamp":1792599155182,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Therapeutic drug monitoring (TDM) of antibiotics has been practiced for more than half a century, but it is still not widely applied for infected patients. It has a traditional focus on limiting toxicity of specific classes of antibiotics such as aminoglycosides and vancomycin. With more patients in critical care with higher levels of sickness severity and immunosuppression as well as an increasingly obese and ageing population, an increasing risk of suboptimal antibiotic exposure continues to escalate. As such, the value of TDM continues to expand, especially for beta-lactams which constitute the most frequently used antibiotic class. To date, the minimum inhibitory concentration (MIC) of infectious microbes rather than classification in terms of susceptible and resistant can be reported. In parallel, increasingly sophisticated TDM technology is becoming available ensuring that TDM is feasible and can deliver personalized antibiotic dosing schemes. There is an obvious need for extensive studies that will quantify the improvements in clinical outcome of individual TDM-guided dosing. We suggest that a broad diagnostic and medical investigation of the TDM arena, including market analyses and analytical technology assessment, is a current priority.<\/jats:p>","DOI":"10.1007\/s10096-019-03769-8","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T12:46:43Z","timestamp":1576068403000},"page":"791-797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Diagnostic and medical needs for therapeutic drug monitoring of antibiotics"],"prefix":"10.1007","volume":"39","author":[{"given":"Claude","family":"Mabilat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Francoise","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"Mouton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Textoris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menino O.","family":"Cotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"van Belkum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Caniaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,11]]},"reference":[{"issue":"10","key":"3769_CR1","first-page":"367","volume":"2","author":"AC Kirkman","year":"1956","unstructured":"Kirkman AC (1956) A review of bacteriological sensitivity tests and a capillary tube method for the determination of antibiotic levels in the body fluids. Cent Afr J Med 2(10):367\u2013369","journal-title":"Cent Afr J Med"},{"issue":"1","key":"3769_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1046\/j.1365-2125.1999.00850.x","volume":"47","author":"EJ Begg","year":"1999","unstructured":"Begg EJ, Barclay ML, Kirkpatrick CJ (1999) The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 47(1):23\u201330 Review","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"3769_CR3","doi-asserted-by":"publisher","first-page":"35S","DOI":"10.1046\/j.1365-2125.2001.00377.x","volume":"52","author":"EJ Begg","year":"2001","unstructured":"Begg EJ, Barclay ML, Kirkpatrick CJ (2001) The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 52(Suppl 1):35S\u201343S","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3769_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2165\/00003088-198409060-00001","volume":"9","author":"M Wenk","year":"1984","unstructured":"Wenk M, Vozeh S, Follath F (1984) Serum level monitoring of antibacterial drugs. A review. Clin Pharmacokinet 9(6):475\u2013492 Review","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"3769_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00228-016-2053-x","volume":"72","author":"F Mattioli","year":"2016","unstructured":"Mattioli F, Fucile C, Del Bono V, Marini V, Parisini A, Molin A, Zuccoli ML, Milano G, Danesi R, Marchese A, Polillo M, Viscoli C, Pelosi P, Martelli A, Di Paolo A (2016) Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Eur J Clin Pharmacol 72(7):839\u2013848. https:\/\/doi.org\/10.1007\/s00228-016-2053-x","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3769_CR6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL, International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14(6):498\u2013509. https:\/\/doi.org\/10.1016\/S1473-3099(14)70036-2","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"3769_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.diagmicrobio.2014.04.007","volume":"79","author":"TW Felton","year":"2014","unstructured":"Felton TW, Hope WW, Roberts JA (2014) How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it? Diagn Microbiol Infect Dis 79(4):441\u2013447. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2014.04.007","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"3769_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40265-018-0880-z","volume":"78","author":"AE Muller","year":"2018","unstructured":"Muller AE, Huttner B, Huttner A (2018) Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections? Drugs. 78(4):439\u2013451. https:\/\/doi.org\/10.1007\/s40265-018-0880-z","journal-title":"Drugs."},{"issue":"6","key":"3769_CR9","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1378\/chest.126.6.1770","volume":"126","author":"J Li","year":"2004","unstructured":"Li J, Burzynski JN, Lee YA, Berg D, Driver CR, Ridzon R, Munsiff SS (2004) Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. Chest. 126(6):1770\u20131776","journal-title":"Chest."},{"issue":"12","key":"3769_CR10","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1093\/jac\/dkw324","volume":"71","author":"SE Boyd","year":"2016","unstructured":"Boyd SE, Charani E, Lyons T, Frost G, Holmes AH (2016) Information provision for antibacterial dosing in the obese patient: a sizeable absence? J Antimicrob Chemother 71(12):3588\u20133592","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"3769_CR11","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/jac\/48.6.887","volume":"48","author":"MD Stickland","year":"2001","unstructured":"Stickland MD, Kirkpatrick CM, Begg EJ, Duffull SB, Oddie SJ, Darlow BA (2001) An extended interval dosing method for gentamicin in neonates. J Antimicrob Chemother 48(6):887\u2013893","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"3769_CR12","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1089\/sur.2014.250","volume":"16","author":"AL Hollis","year":"2015","unstructured":"Hollis AL, Heil EL, Nicolau DP, Odonkor P, Dowling TC, Thom KA (2015) Validation of a dosing strategy for cefazolin for surgery requiring cardiopulmonary bypass. Surg Infect 16(6):829\u2013832. https:\/\/doi.org\/10.1089\/sur.2014.250","journal-title":"Surg Infect"},{"issue":"1","key":"3769_CR13","first-page":"47","volume":"41","author":"E Delfino","year":"2018","unstructured":"Delfino E, Fucile C, Del Bono V, Marchese A, Marini V, Coppo E, Casciaro R, Minicucci L, Giacobbe DR, Martelli A, Viscoli C, Mattioli F (2018) Pharmacokinetics of high-dose extended-infusion meropenem during pulmonary exacerbation in adult cystic fibrosis patients: a case series. New Microbiol 41(1):47\u201351","journal-title":"New Microbiol"},{"issue":"5","key":"3769_CR14","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/MCC.0b013e32835685ad","volume":"18","author":"JA Jamal","year":"2012","unstructured":"Jamal JA, Economou CJ, Lipman J, Roberts JA (2012) Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care 18(5):460\u2013471. https:\/\/doi.org\/10.1097\/MCC.0b013e32835685ad","journal-title":"Curr Opin Crit Care"},{"issue":"1","key":"3769_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.diagmicrobio.2015.01.013","volume":"82","author":"JA Jamal","year":"2015","unstructured":"Jamal JA, Mueller BA, Choi GY, Lipman J, Roberts JA (2015) How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy? Diagn Microbiol Infect Dis 82(1):92\u2013103. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2015.01.013","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"8","key":"3769_CR16","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, DALI study (2014) DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58(8):1072\u20131083. https:\/\/doi.org\/10.1093\/cid\/ciu027","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3769_CR17","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1128\/AAC.00294-06","volume":"51","author":"C Li","year":"2007","unstructured":"Li C, Du X, Kuti JL, Nicolau DP (2007) Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51(5):1725\u20131730","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3769_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","volume":"31","author":"PS McKinnon","year":"2008","unstructured":"McKinnon PS, Paladino JA, Schentag JJ (2008) Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31(4):345\u2013351. https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.12.009","journal-title":"Int J Antimicrob Agents"},{"issue":"April","key":"3769_CR19","first-page":"12","volume":"2017","author":"A Abdulla","year":"2017","unstructured":"Abdulla A, Hunfeld N, Dijkstra A, Duran S, Mouton J, Gommers D, van Gelder T, Koch B (2017) Beta-lactam and quinolone pharmacokinetic\/pharmacodynamic target attainment in critically ill patients (EXPAT). Abstr ECCMID 2017(April):12\u201313","journal-title":"Abstr ECCMID"},{"issue":"3","key":"3769_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ijantimicag.2017.11.013","volume":"51","author":"C Carri\u00e9","year":"2018","unstructured":"Carri\u00e9 C, Petit L, d'Houdain N, Sauvage N, Cottenceau V, Lafitte M, Foumenteze C, Hisz Q, Menu D, Legeron R, Breilh D, Sztark F (2018) Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of \u03b2-lactams administered by continuous infusion: a prospective observational study. Int J Antimicrob Agents 51(3):443\u2013449. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.11.013","journal-title":"Int J Antimicrob Agents"},{"issue":"13","key":"3769_CR21","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","volume":"43","author":"PA Moise-Broder","year":"2004","unstructured":"Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ (2004) Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43(13):925\u2013942","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3769_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/600877","volume":"49","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP (2009) Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49(3):325\u2013327. https:\/\/doi.org\/10.1086\/600877","journal-title":"Clin Infect Dis"},{"key":"3769_CR23","doi-asserted-by":"publisher","unstructured":"Martirosov D, Bidell M, Pai M, Scheetz M, Rosenkranz S, Lodise T (2017) Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest\u00ae MIC values of 1.5 mg\/L: a pilot study. Diagn Microbiol Infect Dis 88. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.03.008","DOI":"10.1016\/j.diagmicrobio.2017.03.008"},{"key":"3769_CR24","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","volume":"37","author":"A Forrest","year":"1993","unstructured":"Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073\u20131081","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3769_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2165\/00003088-200948040-00005","volume":"48","author":"M Fern\u00e1ndez de Gatta","year":"2009","unstructured":"Fern\u00e1ndez de Gatta M, Santos Buelga D, S\u00e1nchez Navarro A, Dominguez-Gil A, Garc\u00eda MJ (2009) Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic\/pharmacodynamic analysis. Clin Pharmacokinet 48(4):273\u2013280. https:\/\/doi.org\/10.2165\/00003088-200948040-00005","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"3769_CR26","doi-asserted-by":"publisher","first-page":"e00485","DOI":"10.1128\/AAC.00485-17","volume":"61","author":"MC Arendrup","year":"2017","unstructured":"Arendrup MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A (2017) Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob Agents Chemother 61(6):e00485\u2013e00417. https:\/\/doi.org\/10.1128\/AAC.00485-17","journal-title":"Antimicrob Agents Chemother"},{"key":"3769_CR27","doi-asserted-by":"publisher","unstructured":"Lopez B, Siqueira de Oliveira R, Pinhata JMW, Chimara E, Pacheco Ascencio E, Puy\u00e9n Guerra ZM, Wainmayer I, Simboli N, Del Granado M, Palomino JC, Ritacco V, Martin A. Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region. J Antimicrob Chemother 2019;74(2):373\u2013379. doi: https:\/\/doi.org\/10.1093\/jac\/dky414","DOI":"10.1093\/jac\/dky414"},{"issue":"3","key":"3769_CR28","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkx427","volume":"73","author":"JW Mouton","year":"2018","unstructured":"Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J (2018) MIC-based dose adjustment: facts and fables. J Antimicrob Chemother 73(3):564\u2013568. https:\/\/doi.org\/10.1093\/jac\/dkx427","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"3769_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1469-0691.2011.03703.x","volume":"19","author":"R Leclercq","year":"2013","unstructured":"Leclercq R, Cant\u00f3n R, Brown DF, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G (2013) EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19(2):141\u2013160. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03703.x","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"3769_CR30","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/jac\/dkx001","volume":"72","author":"VH Tam","year":"2017","unstructured":"Tam VH, Chang KT, Zhou J, Ledesma KR, Phe K, Gao S, Van Bambeke F, S\u00e1nchez-D\u00edaz AM, Zamorano L, Oliver A, Cant\u00f3n R (2017) Determining \u03b2-lactam exposure threshold to suppress resistance development in gram-negative bacteria. J Antimicrob Chemother 72(5):1421\u20131428. https:\/\/doi.org\/10.1093\/jac\/dkx001","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"3769_CR31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","volume":"194","author":"JA Roberts","year":"2016","unstructured":"Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, Bellomo R, Lipman J (2016) Continuous versus intermittent \u03b2-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med 194(6):681\u2013691. https:\/\/doi.org\/10.1164\/rccm.201601-0024OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3769_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","volume":"18","author":"KZ Vardakas","year":"2018","unstructured":"Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME (2018) Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis 18(1):108\u2013120. https:\/\/doi.org\/10.1016\/S1473-3099(17)30615-1","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"3769_CR33","doi-asserted-by":"publisher","first-page":"e01602","DOI":"10.1128\/AAC.01602-17","volume":"62","author":"MTB Jumah","year":"2018","unstructured":"Jumah MTB, Vasoo S, Menon SR, De PP, Neely M, Teng CB (2018) Pharmacokinetic\/pharmacodynamic determinants of vancomycin efficacy in enterococcal bacteremia. Antimicrob Agents Chemother 62(3):e01602\u2013e01617. Published 2018 Feb 23. https:\/\/doi.org\/10.1128\/AAC.01602-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3769_CR34","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/jac\/dkg403","volume":"52","author":"SA Zelenitsky","year":"2003","unstructured":"Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE (2003) Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 52(4):668\u2013674","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"3769_CR35","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","volume":"42","author":"MH Abdul-Aziz","year":"2016","unstructured":"Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, Rai V, Wong KK, Hasan MS, Abd Rahman AN, Jamal JA, Wallis SC, Lipman J, Staatz CE, Roberts JA (2016) Beta-Lactam Infusion In Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med 42(10):1535\u20131545. https:\/\/doi.org\/10.1007\/s00134-015-4188-0","journal-title":"Intensive Care Med"},{"issue":"4","key":"3769_CR36","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/jac\/dks468","volume":"68","author":"AE Muller","year":"2013","unstructured":"Muller AE, Punt N, Mouton JW (2013) Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother 68(4):900\u2013906. https:\/\/doi.org\/10.1093\/jac\/dks468","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"3769_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","volume":"155","author":"RD Moore","year":"1987","unstructured":"Moore RD, Lietman PS, Smith CR (1987) Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155(1):93\u201399","journal-title":"J Infect Dis"},{"issue":"3","key":"3769_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ijantimicag.2012.10.015","volume":"41","author":"S Zelenitsky","year":"2013","unstructured":"Zelenitsky S, Rubinstein E, Ariano R, Iacovides H, Dodek P, Mirzanejad Y, Kumar A (2013) The Cooperative Antimicrobial Therapy of Septic Shock (CATSS) database research group. Int J Antimicrob Agents 41(3):255\u2013260","journal-title":"Int J Antimicrob Agents"},{"key":"3769_CR39","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1128\/AAC.45.10.2793-2797.2001","volume":"45","author":"PG Ambrose","year":"2001","unstructured":"Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF (2001) Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 45:2793\u20132797","journal-title":"Antimicrob Agents Chemother"},{"key":"3769_CR40","doi-asserted-by":"crossref","unstructured":"Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ Clinical pharmadynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin. Pharmacokinet 42(15):1411\u20131423","DOI":"10.2165\/00003088-200342150-00007"},{"issue":"1","key":"3769_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ijantimicag.2018.09.015","volume":"53","author":"A Galar","year":"2019","unstructured":"Galar A, Mu\u00f1oz P, Valerio M, Cercenado E, Garc\u00eda-Gonz\u00e1lez X, Burillo A, S\u00e1nchez-Somolinos M, Ju\u00e1rez M, Verde E, Bouza E (2019) Current use of daptomycin and systematic therapeutic drug monitoring: clinical experience in a tertiary care institution. Int J Antimicrob Agents 53(1):40\u201348. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.09.015","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"3769_CR42","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1128\/AAC.49.8.3171-3177.2005","volume":"49","author":"CJ Clancy","year":"2005","unstructured":"Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH (2005) Fluconazole MIC and the fluconazole dose\/MIC ratio correlate with therapeutic response among patients with candidemia. Agents Chemother 49(8):3171\u20133177","journal-title":"Agents Chemother"},{"issue":"1","key":"3769_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1365-2125.2011.04080.x","volume":"73","author":"JA Roberts","year":"2012","unstructured":"Roberts JA, Norris R, Paterson DL, Martin JH (2012) Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 73(1):27\u201336. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04080.x","journal-title":"Br J Clin Pharmacol"},{"key":"3769_CR44","unstructured":"OPTIMAL TDM study. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03790631"},{"issue":"6","key":"3769_CR45","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1128\/AAC.05360-11","volume":"56","author":"MN Martinez","year":"2012","unstructured":"Martinez MN, Papich MG, Drusano GL (2012) Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic\/pharmacodynamic target. Antimicrob Agents Chemother 56(6):2795\u20132805. https:\/\/doi.org\/10.1128\/AAC.05360-11","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"3769_CR46","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1128\/AAC.00461-13","volume":"57","author":"B Vanscoy","year":"2013","unstructured":"Vanscoy B, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Forrest A, Jones RN, Okusanya OO, Friedrich LV, Steenbergen J, Ambrose PG (2013) Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Antimicrob Agents Chemother 57(9):4134\u20134138. https:\/\/doi.org\/10.1128\/AAC.00461-13","journal-title":"Antimicrob Agents Chemother"},{"key":"3769_CR47","doi-asserted-by":"publisher","unstructured":"Jacobs A, Taccone FS, Roberts JA, Jacobs F, Cotton F, Wolff F, Creteur J, Vincent JL, Hites M. \u03b2-Lactam dosage regimens in septic patients with augmented renal clearance. Antimicrob Agents Chemother. 2018;62(9). pii: e02534\u2013e02517. doi: https:\/\/doi.org\/10.1128\/AAC.02534-17.","DOI":"10.1128\/AAC.02534-17"},{"key":"3769_CR48","unstructured":"Roehr AC, Frey OR, K\u00f6berer A, Fuchs T, Helbig S, Brinkmann A, Mouton JW (2015) Creatinine-clearance as predictor for meropenem clearance. ESCMID Copenhagen, nr:EV0080"},{"issue":"1","key":"3769_CR49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","volume":"21","author":"NA Van Lent-Evers","year":"1999","unstructured":"Van Lent-Evers NA, Math\u00f4t RA, Geus WP, van Hout BA, Vinks AA (1999) Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 21(1):63\u201373","journal-title":"Ther Drug Monit"},{"issue":"11","key":"3769_CR50","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1586\/14787210.2014.966081","volume":"12","author":"C Stockmann","year":"2014","unstructured":"Stockmann C, Roberts JK, Yu T, Constance JE, Knibbe CA, Spigarelli MG, Sherwin CM (2014) Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. Expert Rev Anti-Infect Ther 12(11):1371\u20131388. https:\/\/doi.org\/10.1586\/14787210.2014.966081","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"5","key":"3769_CR51","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/jac\/dkt523","volume":"69","author":"G Wong","year":"2014","unstructured":"Wong G, Brinkman A, Benefield RJ, Carlier M, De Waele JJ, El Helali N, Frey O, Harbarth S, Huttner A, McWhinney B, Misset B, Pea F, Preisenberger J, Roberts MS, Robertson TA, Roehr A, Sime FB, Taccone FS, Ungerer JP, Lipman J, Roberts JA (2014) An international, multicentre survey of \u03b2-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 69(5):1416\u20131423. https:\/\/doi.org\/10.1093\/jac\/dkt523","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"3769_CR52","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1073\/pnas.1613458114","volume":"114","author":"N Arroyo-Curr\u00e1s","year":"2017","unstructured":"Arroyo-Curr\u00e1s N, Somerson J, Vieira PA, Ploense KL, Kippin TE, Plaxco KW (2017) Real-time measurement of small molecules directly in awake, ambulatory animals. Proc Natl Acad Sci U S A 114(4):645\u2013650. https:\/\/doi.org\/10.1073\/pnas.1613458114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"3769_CR53","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/jac\/dkx458","volume":"73","author":"TM Rawson","year":"2018","unstructured":"Rawson TM, O'Hare D, Herrero P, Sharma S, Moore LSP, de Barra E, Roberts JA, Gordon AC, Hope W, Georgiou P, Cass AEG, Holmes AH (2018) Delivering precision antimicrobial therapy through closed-loop control systems. J Antimicrob Chemother 73(4):835\u2013843. https:\/\/doi.org\/10.1093\/jac\/dkx458","journal-title":"J Antimicrob Chemother"},{"key":"3769_CR54","doi-asserted-by":"crossref","unstructured":"Rawson TM, Gowers SAN, Freeman DME, Wilson RC, Sharma S, Gilchrist M, MacGowan M, Lovering A, Bayliss M, Kyriakides M, Georgiou P, Cass AE, O\u2019Hare D, Holmes AH (2019) Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers. Lancet Digital Health Published online September 30, 2019","DOI":"10.1016\/S2589-7500(19)30131-1"},{"issue":"1","key":"3769_CR55","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.3390\/bios9010019","volume":"9","author":"ZT Al-Aqbi","year":"2019","unstructured":"Al-Aqbi ZT, Yap YC, Li F, Breadmore MC (2019) Integrated microfluidic devices fabricated in poly (methyl methacrylate) (PMMA) for on-site therapeutic drug monitoring of aminoglycosides in whole blood. Biosensors (Basel) 9(1):E19. https:\/\/doi.org\/10.3390\/bios9010019","journal-title":"Biosensors (Basel)"},{"issue":"4","key":"3769_CR56","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1021\/acssensors.9b00288","volume":"4","author":"SAN Gowers","year":"2019","unstructured":"Gowers SAN, Freeman DME, Rawson TM, Rogers ML, Wilson RC, Holmes AH, Cass AE, O'Hare D (2019) Development of a minimally invasive microneedle-based sensor for continuous monitoring of \u03b2-lactam antibiotic concentrations in vivo. ACS Sens 4(4):1072\u20131080. https:\/\/doi.org\/10.1021\/acssensors.9b00288","journal-title":"ACS Sens"},{"key":"3769_CR57","doi-asserted-by":"publisher","unstructured":"Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ, van der Werf TS, Shrestha B, Alffenaar JC. Evaluation of saliva as a potential alternative sampling matrix for therapeutic drug monitoring of levofloxacin in patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2019;63(5). pii: e02379\u2013e02318. doi: https:\/\/doi.org\/10.1128\/AAC.02379-18","DOI":"10.1128\/AAC.02379-18"},{"key":"3769_CR58","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.phrs.2018.07.005","volume":"134","author":"F De Velde","year":"2018","unstructured":"De Velde F, Mouton JW, de Winter BCM, van Gelder T, Koch BCP (2018) Clinical applications of population pharmacokinetic models of antibiotics: challenges and perspectives. Pharmacol Res 134:280\u2013288. https:\/\/doi.org\/10.1016\/j.phrs.2018.07.005","journal-title":"Pharmacol Res"},{"issue":"2","key":"3769_CR59","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/CCM.0000000000002836","volume":"46","author":"NJ Rhodes","year":"2018","unstructured":"Rhodes NJ, Liu J, O'Donnell JN, Dulhunty JM, Abdul-Aziz MH, Berko PY, Nadler B, Lipman J, Roberts JA (2018) Prolonged infusion piperacillin-tazobactam decreases mortality and improves outcomes in severely ill patients: results of a systematic review and meta-analysis. Crit Care Med 46(2):236\u2013243. https:\/\/doi.org\/10.1097\/CCM.0000000000002836","journal-title":"Crit Care Med"},{"key":"3769_CR60","doi-asserted-by":"publisher","unstructured":"Alvarez-Lorenzo C, Concheiro A (2019) Smart drug release from medical devices. J Pharmacol Exp Ther. https:\/\/doi.org\/10.1124\/jpet.119.257220","DOI":"10.1124\/jpet.119.257220"},{"issue":"1","key":"3769_CR61","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/jac\/38.1.5","volume":"38","author":"JW Mouton","year":"1996","unstructured":"Mouton JW, Vinks AA (1996) Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations. J Antimicrob Chemother 38(1):5\u201315","journal-title":"J Antimicrob Chemother"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03769-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-019-03769-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03769-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T01:01:18Z","timestamp":1607562078000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-019-03769-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,11]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["3769"],"URL":"https:\/\/doi.org\/10.1007\/s10096-019-03769-8","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,11]]},"assertion":[{"value":"11 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}